We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+5.08%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.49B
AUM Growth
+$37.4M
Cap. Flow
-$505M
Cap. Flow %
-20.29%
Top 10 Hldgs %
34.18%
Holding
156
New
33
Increased
30
Reduced
32
Closed
28

Top Buys

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$84.9M
2
EHTH icon
eHealth
EHTH
+$41.7M
3
KERX
Keryx Biopharmaceuticals Inc
KERX
+$35.2M
4
AGN
Allergan Inc
AGN
+$34M
5
ITMN
INTERMUNE INC
ITMN
+$26.9M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$87.6M
2
LH icon
Labcorp
LH
+$56.3M
3
MRK icon
Merck
MRK
+$27.1M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$26.4M
5
DGX icon
Quest Diagnostics
DGX
+$25.5M

Sector Composition

Rank Sector Weight
1 Healthcare 42.33%
2 Financials 2.57%
3 Technology 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AET
51
DELISTED
Aetna Inc
AET
$13.7M 0.55%
+168,850
New +$12.8M
PETX
52
DELISTED
Aratana Therapeutics, Inc.
PETX
$12.3M 0.5%
788,904
– –
INGN icon
53
Inogen
INGN
$173M
$11.9M 0.48%
527,337
+170,068
+48% +$2.82M
IMS
54
DELISTED
IMS HEALTH HLDGS INC COM STK (DE)
IMS
$11.9M 0.48%
+462,350
New +$11.1M
IMMU
55
DELISTED
Immunomedics Inc
IMMU
$10.2M 0.41%
2,805,972
+177,000
+7% +$650K
HZNP
56
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$9.69M 0.39%
612,787
-698,143
-53% -$9.96M
GNCA
57
DELISTED
Genocea Biosciences, Inc.
GNCA
$9.06M 0.36%
60,402
-22,096
-27% -$3.35M
VRTX icon
58
Vertex Pharmaceuticals
VRTX
$122B
$8.76M 0.35%
92,500
+14,000
+18% +$982K
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
$8.72M 0.35%
256,500
+139,811
+120% +$4.38M
RIGL icon
60
Rigel Pharmaceuticals
RIGL
$734M
$8.7M 0.35%
239,786
+137,042
+133% +$4.66M
STRM
61
DELISTED
Streamline Health Solutions
STRM
$8.27M 0.33%
114,840
+38,833
+51% +$2.88M
ALIM
62
DELISTED
Alimera Sciences
ALIM
$7.84M 0.32%
87,419
– –
LITS
63
Lite Strategy Inc
LITS
$35M
$7.18M 0.29%
56,619
-1,610
-3% -$236K
KIN
64
DELISTED
Kindred Biosciences, Inc.
KIN
$6.99M 0.28%
+375,000
New +$6.37M
NSTG
65
DELISTED
NanoString Technologies, Inc.
NSTG
$6.79M 0.27%
454,281
+63,176
+16% +$995K
WINT
66
DELISTED
Windtree Therapeutics Inc
WINT
$6.51M 0.26%
261,407
– –
ATEC icon
67
Alphatec Holdings
ATEC
$1.27B
$6.49M 0.26%
331,895
– –
CASM
68
DELISTED
CAS Medical Systems, Inc.
CASM
$6.43M 0.26%
3,200,000
– –
KBIO
69
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$6.35M 0.26%
348,348
– –
ALNY icon
70
Alnylam Pharmaceuticals
ALNY
$36.4B
$6.32M 0.25%
100,000
-202,000
-67% -$12M
CNCE
71
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.24M 0.25%
617,649
– –
DSCI
72
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$5.99M 0.24%
517,900
+217,900
+73% +$2.24M
ANTH
73
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.74M 0.23%
211,482
– –
POZN
74
DELISTED
POZEN INC
POZN
$5.2M 0.21%
+624,621
New +$5.37M
LPDX
75
DELISTED
LIPOSCIENCE INC COM
LPDX
$4.73M 0.19%
1,382,350
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2014 Portfolio in Review

As of Q2 2014, Deerfield Management held 156 positions worth $2.49B, up 1.5% from $2.45B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $505M in Q2 2014, closing 28 positions and reducing 32 holdings. Its most notable exit was Merck, an estimated $27.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 44% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK worth $23.1M.

  • Deerfield Management's largest Q2 2014 buy was TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK: 1,482,666 shares worth $23.1M.
  • Deerfield Management added most to AUXILIUM PHARAMCEUTICALS INC in Q2 2014, an estimated $84.9M increase.
  • Deerfield Management's biggest Q2 2014 reduction was QUESTCOR PHARMA INC, cutting an estimated $87.6M.
  • Deerfield Management fully exited Merck in Q2 2014, selling an estimated $27.1M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.49B portfolio in Q2 2014.
  • Deerfield Management opened 33 new positions and closed 28 in Q2 2014.
  • Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.49B.

Based on Deerfield Management's 13F filing for Q2 2014, filed 14 Aug 2014.